CM
IMVT icon

Castleark Management’s Immunovant IMVT Stock Holding History

Castleark Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,190
Closed -$137K – 291
2024
Q2 		$137K Sell
5,190
-75,250
-94% -$2.14M 0.01% 249
2024
Q1 		$2.6M Buy
+80,440
New +$2.93M 0.11% 165

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Castleark Management's IMVT Position: Q3 2024 in Review

Castleark Management sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 5,190 shares — an estimated $137K sold.

Castleark Management first reported a position in IMVT in Q1 2024 and held it in 2 quarters. The position peaked at $2.6M in Q1 2024. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Castleark Management reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Castleark Management sold 5,190 Immunovant shares in Q3 2024, an estimated $137K.
  • Castleark Management first reported a position in Immunovant in Q1 2024 and held it in 2 quarters.
  • Castleark Management's Immunovant position peaked at $2.6M in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Castleark Management's 13F filing for Q3 2024, filed 15 Nov 2024.